AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02221011 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impulsivity screening
Description: Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
Study NCT03506750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive screening
Description: Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
Study NCT03506750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.
Study NCT03506750 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional tests
Description: Timed up and go (TUG), Single leg balancing test (SLB)
Study NCT03506750 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.
Study NCT02221011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
Study NCT02458274 — intervention group
Intervention type: OTHER
Intervention: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)
Study NCT04222088 — intervention group
Intervention type: DRUG
Intervention: Arthemeter-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)
Study NCT04222088 — intervention group
Intervention type: DRUG
Intervention: Chloroquine
Description: Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
Study NCT04222088 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study NCT03311997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical reattachment of hamstring tendons
Description: operatively reattachment of the tendons using suture anchor
Study NCT01071317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg PO bid prn headache
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognistat
Description: Assessment of cognitive domains
Study NCT03506750 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IVC-sham
Description: Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological profiling
Description: Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
Study NCT03162081 — intervention group
Intervention type: OTHER
Intervention: Clinical interview
Description: Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
Study NCT03162081 — intervention group
Intervention type: OTHER
Intervention: Medication use
Description: Detailed screen of used medications, interactions, side effects in electronic patient registry
Study NCT03162081 — intervention group
Intervention type: OTHER
Intervention: Comorbidity
Description: Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
Study NCT02801942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node fine needle aspirate biopsy
Description: Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
Study NCT02801942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node core biopsy
Description: Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
Study NCT01359189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProxiScan (scintigraphic rectal probe)
Description: ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used.
Study NCT04228601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP
Study NCT04228601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzoparib placebo
Description: Placebo
Study NCT02801942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Blood sample (30 mL) will be collected, to derive immune cells.
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02801942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre- and post-biopsy questionnaire
Description: All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
Study NCT00218296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Nicotine replacement therapy
Study NCT00218296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction Group
Description: Subject selects preferred method for reduction.
Study NCT01094496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1307 Vaccine Regimen
Description: CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
Study NCT01094496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02717988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient
Study NCT02717988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo 180 mg capsule filled with microcrystalline cellulose
Study NCT02212587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOBI
Description: New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
Study NCT03395158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Implementation of new alert criteria
Description: The intervention is when the prior alert criteria are replaced by the present alert criteria
Study NCT01415063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Study NCT01415063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE-RFA
Description: TACE first, then RFA within 2 weeks
Study NCT04344314 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral Intravenous Catheter
Description: Randomised controlled
Study NCT04228601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX
Study NCT01071317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: 100mg po q day prn headache
Study NCT01071317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine education
Description: Educational program available through NIH/ national library of medicine/ X-plain
Study NCT01071317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reenforcement of diagnosis
Description: Patient advised has migraine headache and how the headache meets migraine criteria
Study NCT01071317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical care
Description: Care to be determined by attending physician
Study NCT03899909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SAD
Description: Placebo oral suspension
Study NCT03899909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121 MAD
Description: GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
Study NCT03899909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MAD
Description: Placebo oral suspension, daily for 13 days
Study NCT04228601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX
Study NCT02263443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soap suds enema (S.S.E.)
Description: Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
Study NCT02263443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium chloride enema
Description: Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
Study NCT02263443 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No enema
Description: Patients NPO groups will NPO and no bowel preparation.
Study NCT01836328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral /oral methadone ratio 1:2
Description: See arm/group descriptions
Study NCT01836328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral /oral methadone ratio 1:1.2
Description: See arm/group descriptions
Study NCT03287037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS over DLPFC
Description: We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
Study NCT01635803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
Study NCT01635803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5mg ranibizumab administered by monthly interval for six months (6 injections).
Study NCT03964688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: vitamin C intravenous during hospitalization, after oral, total 6 weeks.
Study NCT03964688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo intravenous during hospitalization, after oral, total 6 weeks
Study NCT00386165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: larazotide acetate 4 mg capsules
Study NCT00386165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: larazotide acetate
Description: larazotide acetate 4 mg capsules
Study NCT02396368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
Study NCT03500133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Description: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Study NCT03500133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN 30Gy RT in case of PR at the end of chemotherapy
Description: Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Description: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study NCT03500133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Study NCT01906710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated medicines management
Description: PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge
Study NCT04911283 — intervention group
Intervention type: OTHER
Intervention: Brucella serology test
Description: MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
Study NCT04911283 — intervention group
Intervention type: OTHER
Intervention: Medical history for brucellosis
Description: Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
Study NCT01666665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study NCT00324467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)